%0 Journal Article
%A Kebir, Sied
%A Schaub, Christina
%A Junold, Nina
%A Hattingen, Elke
%A Schäfer, Niklas
%A Steinbach, Joachim P.
%A Weyerbrock, Astrid
%A Hau, Peter
%A Goldbrunner, Roland
%A Galldiks, Norbert
%A Weller, Johannes
%A Mack, Frederic
%A Tzaridis, Theophilos
%A Bähr, Oliver
%A Seidel, Clemens
%A Schlegel, Uwe
%A Schmidt-Graf, Friederike
%A Rohde, Veit
%A Borchers, Christian
%A Tabatabai, Ghazaleh
%A Hänel, Mathias
%A Sabel, Michael
%A Gerlach, Rüdiger
%A Krex, Dietmar
%A Belka, Claus
%A Vatter, Hartmut
%A Proescholdt, Martin
%A Glas, Martin
%A Herrlinger, Ulrich
%T Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
%J Journal of neuro-oncology
%V 144
%N 3
%@ 1573-7373
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M FZJ-2019-03906
%P 501-509
%D 2019
%X PurposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset.MethodsMRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival.ResultsMRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival.ConclusionsBaseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31325144
%U <Go to ISI:>//WOS:000487899900008
%R 10.1007/s11060-019-03246-4
%U https://juser.fz-juelich.de/record/863990